- 3-PYRIMIDIN-4-YL-OXAZOLIDIN-2-ONES AS INHIBITORS OF MUTANT IDH
-
The invention is directed to a formula (I): or a pharmaceutically acceptable salt thereof, wherein R1, R2a, R2b and R3-R7 are described herein. The invention is also directed to compositions containing a compound of formula (I) and to the use of such compounds in the inhibition of mutant IDH proteins having a neomorphic activity. The invention is further directed to the use of a compound of formula (I) in the treatment of diseases or disorders associated with such mutant I DH proteins including, but not limited to, cell-proliferation disorders, such as cancer.
- -
-
Page/Page column 66; 67
(2014/09/29)
-
- 3-PYRIMIDIN-4-YL-OXAZOLIDIN-2-ONES AS INHIBITORS OF MUTANT IDH
-
The invention is directed to a formula (I), or a pharmamceutically acceptable salt thereof, wherein R1, R2a, R2b and R3-R7 are herein. The invention is also directed to compositions containing a compound of formula (I) and to the use of such compounds in the inhibition of mutant IDH proteins having a neomorphic activity. The invention is further directed to the use of a compound of formula (I) in the treatment of diseases or disorders associated with such mutant IDH proteins including, but not limited to, cell-proliferation disorders, such as cancer.
- -
-
Page/Page column 156
(2014/09/29)
-
- NOVEL PYRIMIDINE-PYRIDINE DERIVATIVES
-
The invention relates to novel pyrimidine-pyridine derivatives, their preparation and their use as pharmaceutically active compounds. Said compounds particularly act as immunomodulating agents.
- -
-
Page/Page column 18
(2011/04/14)
-
- PYRIDINE DERIVATIVES AS S1P1/EDG1 RECEPTOR MODULATORS
-
The invention relates to novel pyridine derivatives of formula (D, their preparation and their use as pharmaceutically active compounds. Said compounds particularly act as immunomodulating agents. Formula (I) wherein A represents and the other substituents are as defined in the claims.
- -
-
Page/Page column 21
(2011/09/20)
-
- Pyridin-3-yl derivatives as immunomodulating agents
-
The invention relates to pyridin-3-yl derivatives of Formula (I) wherein R1, R2, R3, R4, R5; R6 and A are as described in the description, their preparation and their use as pharmaceuticall
- -
-
Page/Page column 13
(2010/07/08)
-
- PYRIDINE DERIVATIVES AS S1P1/EDG1 RECEPTOR MODULATORS
-
The invention relates to novel pyridine derivatives of formula (D, their preparation and their use as pharmaceutically active compounds. Said compounds particularly act as immunomodulating agents. Formula (I) wherein A represents and the other substituants are as defined in the claims.
- -
-
Page/Page column 56; 61
(2009/04/25)
-
- PYRIDINE COMPOUNDS
-
The invention relates to pyridine compounds, their preparation and their use as pharmaceutically active compounds. Said compounds particularly act as immunomodulating agents.
- -
-
Page/Page column 21
(2009/10/22)
-
- NOVEL PYRIMIDINE-PYRIDINE DERIVATIVES
-
The invention relates to novel pyrimidine-pyridine derivatives, their preparation and their use as pharmaceutically active compounds. Said compounds particularly act as immunomodulating agents. Formula I.
- -
-
Page/Page column 44
(2009/10/22)
-
- PYRIDIN-3-YL DERIVATIVES AS IMMUNOMODULATING AGENTS
-
The invention relates to pyridin-3-yl derivatives of Formula (I) wherein R1, R2, R3, R4, R5; R6 and A are as described in the description, their preparation and their use as pharmaceuticall
- -
-
Page/Page column 31; 32
(2008/06/13)
-
- PROLINE DERIVATIVES AND USE THEREOF AS DRUGS
-
The present invention aims at providing compounds having therapeutic effects due to a DPP-IV inhibitory action, and satisfactory as pharmaceutical products. The present inventors have found that derivatives having a substituent introduced into the γ-position of proline represented by the formula (I) wherein each symbol is as defined in the specification, have a potent DPP-IV inhibitory activity, and completed the present invention by increasing the stability.
- -
-
-